Haleon (NYSE:HLN) Rating Increased to Outperform at BNP Paribas Exane

Haleon (NYSE:HLN - Get Free Report) was upgraded by analysts at BNP Paribas Exane from a "neutral" rating to an "outperform" rating in a research note issued on Tuesday, Marketbeat Ratings reports. The brokerage presently has a $13.40 price objective on the stock. BNP Paribas Exane's price target points to a potential upside of 18.90% from the company's current price.

A number of other analysts have also recently commented on the company. Barclays reiterated an "overweight" rating on shares of Haleon in a research report on Tuesday, May 6th. Wall Street Zen lowered Haleon from a "buy" rating to a "hold" rating in a research report on Thursday, May 22nd. Deutsche Bank Aktiengesellschaft reissued a "hold" rating on shares of Haleon in a report on Monday, March 3rd. Morgan Stanley raised shares of Haleon from an "equal weight" rating to an "overweight" rating and set a $11.25 target price on the stock in a report on Friday, May 9th. Finally, HSBC restated a "hold" rating on shares of Haleon in a research report on Wednesday, March 5th. Six investment analysts have rated the stock with a hold rating, four have issued a buy rating and one has assigned a strong buy rating to the company's stock. According to MarketBeat.com, Haleon currently has an average rating of "Moderate Buy" and an average price target of $12.33.

Haleon Stock Up 0.4%

Shares of Haleon stock traded up $0.04 during trading on Tuesday, hitting $11.27. 19,413,998 shares of the stock were exchanged, compared to its average volume of 8,338,135. The company has a debt-to-equity ratio of 0.44, a current ratio of 0.84 and a quick ratio of 0.58. The firm's 50-day moving average price is $10.35 and its 200 day moving average price is $9.94. The stock has a market cap of $50.79 billion, a price-to-earnings ratio of 33.15, a price-to-earnings-growth ratio of 2.82 and a beta of 0.24. Haleon has a 12-month low of $8.25 and a 12-month high of $11.35.

Haleon (NYSE:HLN - Get Free Report) last released its quarterly earnings data on Thursday, February 27th. The company reported $0.05 EPS for the quarter. The business had revenue of $3.54 billion for the quarter, compared to the consensus estimate of $3.38 billion. Haleon had a return on equity of 14.76% and a net margin of 10.85%. As a group, analysts forecast that Haleon will post 0.43 earnings per share for the current fiscal year.

Institutional Trading of Haleon

Several hedge funds have recently modified their holdings of the business. Sierra Ocean LLC acquired a new stake in Haleon in the fourth quarter valued at $26,000. Bartlett & CO. Wealth Management LLC boosted its holdings in Haleon by 135.9% during the first quarter. Bartlett & CO. Wealth Management LLC now owns 2,588 shares of the company's stock worth $27,000 after buying an additional 1,491 shares in the last quarter. Banque Transatlantique SA acquired a new position in Haleon during the first quarter worth about $27,000. Opal Wealth Advisors LLC acquired a new position in Haleon during the first quarter worth about $29,000. Finally, Ransom Advisory Ltd purchased a new position in Haleon in the first quarter valued at about $31,000. 6.67% of the stock is owned by institutional investors and hedge funds.

Haleon Company Profile

Haleon plc, together with its subsidiaries, engages in the research, development, manufacture, and sale of various consumer healthcare products in North America, Europe, the Middle East, Africa, Latin America, and the Asia Pacific. The company provides oral health products, such as toothpastes, mouth washes, and denture care products under the Sensodyne, Polident, Parodontax, Biotene brands; and vitamins, minerals, and supplements under Centrum, Emergen-C, Caltrate brands.